Marker Therapeutics CAO departs; appoints Eliot Lurier as Interim CFO

Marker Therapeutics, Inc.

Michael Loiacono, Chief Accounting Officer, separated effective June 30, 2023.
Company agreed to provide severance benefits consistent with employment agreement upon execution of release.
Eliot M. Lurier appointed Interim CFO effective June 30; serves via Danforth Advisors consulting agreement.
Mr. Lurier, age 65, has served as consultant to life science companies through Danforth since July 2021.
No family relationships or material transactions between Lurier and company officers/directors.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Loiacono

Chief Accounting Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2023-06-30
Filed: July 3, 2023, 7:59 PM ET

Michael Loiacono, the Chief Accounting Officer of Marker Therapeutics, Inc. (the “ Company ”), was separated from the Company.

Appointed (interim)

Eliot M. Lurier

Interim Chief Financial Officer

MRKR · Marker Therapeutics, Inc.

Effective: 2023-06-30
Filed: July 3, 2023, 7:59 PM ET

the Company appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Loiacono departed as Chief Accounting Officer at Marker Therapeutics, Inc..

Action: separated
Role: Chief Accounting Officer

Exact text from the filing

Michael Loiacono, the Chief Accounting Officer of Marker Therapeutics, Inc. (the “ Company ”), was separated from the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Eliot M. Lurier was appointed as Interim Chief Financial Officer at Marker Therapeutics, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

the Company appointed Eliot M. Lurier as the Company’s Interim Chief Financial Officer.

View on SEC.gov

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-077598

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.